Outcomes for T- and NK-cell lymphomas in England
Research type
Research Study
Full title
Real World Outcomes for T- and NK-cell lymphomas in England using National Cancer Registration and Analysis Service Data
IRAS ID
292997
Contact name
Mark Bishton
Contact email
Sponsor organisation
R&I, Nottingham University Hospitals NHS Trust
Duration of Study in the UK
3 years, 1 months, 29 days
Research summary
T- and NK-cell lymphomas are a heterogeneous group of diseases that are aggressive and generally associated with poor prognosis. The WHO currently divides PTCL into over 15 different subtypes based on histologic and immunophenotypic features, with modern diagnostic techniques allowing increasing numbers of specific disease subtypes to be defined over time. The sum of all these separate diseases still comprises less than 10% of all lymphoma in western countries.
Researching T- and NK-cell lymphoma is challenging due to:
• incomplete information about the occurrence and natural course of the diseases
• poor understanding of the reasons why these diseases occur; and
• difficulty identifying large enough numbers of cases to meaningfully answer research questions.
We intend to use high quality information, routinely collected by the Public Health England (PHE) body, the National Cancer Registration and Analysis Service (NCRAS) to find out when, where and in whom cases of T- and NK-cell lymphoma have occurred across the whole of England. We will also investigate what happened to the affected individuals. We will be able to detect any inequalities in diagnosis and survival in relation to age, sex and treatment information recorded by the systemic anti-cancer therapy (SACT) dataset. Our ultimate aim is to bring greater understanding of these rare diseases, facilitate early diagnosis, improve outcomes and the quality of life of patients.REC name
Yorkshire & The Humber - Bradford Leeds Research Ethics Committee
REC reference
21/YH/0128
Date of REC Opinion
7 Jun 2021
REC opinion
Favourable Opinion